Nurix Therapeutics is a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted protein degradation medicines. These innovative therapies aim to enhance treatment options for patients suffering from cancer and inflammatory diseases. Leveraging a fully AI-integrated discovery engine and exceptional ligase expertise, Nurix's team is committed to translating the science of targeted protein degradation into clinical advancements. The company strives to position degrader-based treatments at the forefront of patient care, aiming to redefine the future of medicine in the fight against disease.